Healthcare
Iol Chemicals and Pharmaceuticals Limited (iolcp) Q4 & FY26 Results: Highest-ever Quarterly Revenue with 15%+ Ebitda Margin
IOL Chemicals and Pharmaceuticals Limited (IOLCP) reports Q4 & FY26 results with highest-ever quarterly revenue and significant EBITDA margin growth.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced its financial results for the quarter and full year ended 31st March 2026. The company achieved its highest-ever quarterly revenue, driven by strong momentum across both Pharmaceuticals and Chemicals businesses. EBITDA and PAT recorded significant growth, while margins expanded meaningfully on a year-on-year basis.
Pharmaceuticals Segment Highlights
The Pharmaceuticals business demonstrated strong growth, led by increasing contributions from the non-Ibuprofen portfolio. Key products such as Paracetamol, Metformin, and other APIs witnessed healthy traction, reflecting the company’s ongoing diversification strategy. The improving product mix, combined with IOL’s position as one of the lowest-cost producers in key molecules, supported stronger profitability and margin expansion in the Pharma segment.
Chemicals Segment Performance
The Chemicals business delivered strong performance during the quarter, with segment EBIT nearly doubling year-on-year, supported by improved realizations, stable demand conditions, and operational efficiencies. Capacity enhancements in Ethyl Acetate, Acetic Anhydride along with the addition of Triacetin capacity will further strengthen the company’s manufacturing capabilities, support backward integration, and drive future growth.
Looking Ahead
IOL remains focused on driving disciplined expansion, deepening its presence in regulated as well as non-regulated markets, and enhancing operational efficiencies, supported by a diversified product portfolio and a strong execution track record.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals and Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
IOL gains 61.0% over three months and trades near its 52-week highs. Thin margins at 5.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue contracts at -1.6% CAGR. That signals structural headwinds, not a short-term blip. RSI hits 77, a level that signals the stock runs hot. Notably, buyers drove volume on 20 recent sessions — though at these levels, some profit-taking is normal. The stock rises 61.0% in three months. Yet revenue grows at only -1.6% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of IOL Chemicals and Pharmaceuticals Limited.
GLENMARK
Glenmark Pharmaceuticals Limited (glenmark) Announces IND Submission for ISB 2301
Glenmark Pharmaceuticals Limited (GLENMARK) announces IND submission for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.
Glenmark Pharmaceuticals Limited (GLENMARK) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301. The focus keyword, Glenmark Pharmaceuticals Limited GLENMARK IND Submission, highlights this significant milestone in the company’s oncology pipeline. ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and natural killer (NK) cells.
Advancement in Multispecific Oncology Pipeline
The IND submission marks an important step in advancing Ichnos Glenmark Innovation’s (IGI) multispecific oncology pipeline into clinical development. ISB 2301, engineered using IGI’s proprietary BEAT® Multispecific Platform, combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. This pentaspecific molecule is designed to address biological heterogeneity and immune-suppressive features of solid tumors.
Planned Phase 1 Clinical Trial
IGI plans to initiate a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumors in 2027. Preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, showing favorable pharmacokinetic and tolerability profiles in non-human primates. The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of ISB 2301 in patients with advanced solid tumors.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Glenmark rises 12.3% over three months, with buying pressure holding steady. The PEG of 0.77 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 9.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock trades at 89% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.77 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.
Drug Manufacturers - General
Sai Parenterals Limited (saiparent) Acquires Majority Stake in Bion Therapeutics’ Prescription Business
Sai Parenterals Limited (SAIPARENT) announces acquisition of Bion Therapeutics’ prescription business, adding 16 brands and enhancing market presence.
Sai Parenterals Limited (NSE: SAIPARENT) has announced a strategic move to acquire a majority stake in Bion Therapeutics India Private Limited (Bion), a Hyderabad-based branded formulations prescription business company. This acquisition, executed through its wholly owned subsidiary SP Analytics Private Limited, is expected to be finalized before the end of this month. The transaction will be an all-cash deal, significantly strengthening Sai Parenterals’ presence in India’s prescription market.
Strategic Benefits
The acquisition of Bion Therapeutics will add 16 established brands and around 250 field staff to Sai Parenterals, enhancing its competitive position in the domestic pharmaceutical landscape. Bion’s extensive infrastructure provides immediate access to a broader market, integrating with Sai Parenterals’ manufacturing capabilities to ensure assured supply, consistent quality, and improved margins.
Operational Integration
Bion’s portfolio, currently manufactured by third parties, will progressively transfer to Sai Parenterals’ accredited facilities, which hold TGA-Australia and WHO-GMP accreditations. This move will allow Bion’s brands to leverage Sai Parenterals’ development pipeline and Noumed’s dossier library, offering a wider portfolio to its existing doctor coverage. The critical-care injectable facility, SAICRITI, due for completion in August 2027, will provide a route into hospital and critical-care segments for Bion’s injectable brands.
Forward-Looking Vision
Commenting on the agreement, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, emphasized the strategic importance of this acquisition in converting development capability into branded revenue. The value flows in both directions, with Bion’s portfolio transferring to Sai Parenterals’ facilities and Sai Parenterals’ development pipeline broadening Bion’s market offerings. Further particulars of the transaction will be disclosed at the appropriate stage.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Sai Parenterals Limited
Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.
Sai falls 8.2% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 57.9% and profits at 48.3% CAGR. Both numbers are exceptional. The stock gains 3.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 57.9% and profits at 48.3% CAGR, with D/E of 0.00. Meanwhile, the stock dips 8.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.
Healthcare
Orchid Pharma Limited Unveils ‘soil to Vialfrom’ Initiative
Orchid Pharma Limited (ORCHPHARMA) reports strong Q2 FY27 results with a 148% surge in EBITDA, highlighting the success of its ‘Soil to VialFROM’ initiative.
Orchid Pharma Limited (ORCHPHARMA) has announced impressive financial results for Q2 FY27, marking a significant milestone with its ‘Soil to VialFROM’ initiative. The company’s standalone EBITDA surged by 148% compared to the same period last year, reflecting robust growth and operational efficiency. This remarkable performance underscores the successful integration of Orchid Pharma Limited and Dhanuka Laboratories Ltd., which was sanctioned under the NCLT scheme effective from July 10, 2026.
Financial Performance Highlights
The financial performance for Q2 FY27 showcases a 14% increase in revenue from operations, reaching Rs 341 crore. The gross margin improved to 15%, up from 7% in Q2 FY26. Notably, the EBITDA margin expanded to 12%, highlighting the company’s strong operational leverage. The profit after tax (PAT) for the quarter stood at Rs 37 crore, a substantial improvement from Rs 7 crore in Q2 FY26.
Strategic Growth Initiatives
The ‘Soil to VialFROM’ initiative, which spans from fermentation and biotransformation to finished dosage, is central to Orchid Pharma’s growth strategy. This comprehensive approach not only enhances the company’s capabilities in API manufacturing but also positions it as a leader in the global anti-infectives market. The initiative is expected to drive sustained long-term growth, leveraging Orchid Pharma’s 30 years of expertise in cephalosporin development.
As Orchid Pharma Limited continues to expand its footprint in regulated markets, the company remains committed to innovation and disciplined expansion, aiming to address the growing demand for novel antibiotics and advanced therapeutic solutions.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Orchid Pharma Limited
Orchid Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Orchid holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gains 1.4% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -7.4% in three months on 22.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Orchid Pharma Limited.
-
MAXESTATES3 days agoMax Estates Limited (maxestates) Reimagines Luxury Living Through ‘the Bungalows’
-
Consumer Cyclical1 day agoUflex Limited (NSE: Uflex) Q2 FY27: Strong Performance Amidst Geopolitical Headwinds
-
Consumer Cyclical1 day agoUflex Limited (NSE: Uflex) Q2 FY27: Revenue Up 26.1%, PAT Surges 682.8%
-
SWARAJ3 days agoSwaraj Suiting Limited (swaraj) Q2 FY27: Revenue Grew ~72% and Net Profit Nearly Doubles
-
Solar2 days agoVikram Solar Limited Q2 FY27: Sales Volume Down, Revenue Up, Order Book Expands
-
FUSIONCX3 days agoFusion CX Limited Q2fy27: Revenue Growth 22.1% Yoy, PAT Up 31.3%
-
Computer Hardware2 days agoTvs Electronics Limited (tvselect) Q2/h1-fy27 Earnings Presentation: Revenue Rebounds, Margins Under Pressure
-
Consumer Cyclical2 days agoStanley Lifestyles Limited (stanley) Q2 FY27: Revenue Up 1.6% Yoy and 7.8% Qoq